Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech and keeping the price target at $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Moleculin Biotech’s ongoing clinical trials and financial position. The company is progressing with its Phase 3 MIRACLE trial, which evaluates the efficacy of Annamycin combined with high-dose cytarabine in treating relapsed/refractory acute myeloid leukemia (AML). The trial’s adaptive design and the expected interim data by the end of 2025 are seen as potential catalysts for the stock, especially if the results show a significant therapeutic impact of Annamycin.
Additionally, the historical performance of Annamycin in earlier trials, where it achieved a higher complete remission rate compared to cytarabine alone, supports optimism about the upcoming data. The company’s solid financial footing, with sufficient cash reserves to support ongoing operations, further strengthens the outlook. These elements combined suggest a promising future for Moleculin Biotech, justifying the Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -21.3% and a 26.76% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.